Article

Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer

2023-06-10

Abstract excerpt

Triple-negative breast cancer (TNBC) is an aggressive disease subtype with limited treatment options. Eribulin is a chemotherapeutic approved for the treatment of advanced breast cancer that has been shown to elicit epigenetic changes. We investigated the effect of eribulin treatment on genome-scale DNA methylation patterns in TNBC cells. Following repeated treatment, The results showed that eribulin-induced chang...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 527d9ab1-f6a8-5056-93bd-69a372241041
DOI: 10.1101/2023.06.09.544426

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancerDOI 10.1101/2023.06.09.544426Read

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunitiesSemantic proximity Read

DNA Methyltransferase 3B–Mediated Intratumoral Heterogeneity and Therapeutic Targeting in Breast Cancer Recurrence and MetastasisSemantic proximity Read

Epigenetic Alterations in Triple-Negative Breast Cancer—The Critical Role of Extracellular MatrixSemantic proximity Read

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast CancerSemantic proximity Read

Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancerSemantic proximity Read

Epi-drugs as triple-negative breast cancer treatmentSemantic proximity Read

EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progressSemantic proximity Read

Targeting DNA Methylation for Treating Triple-Negative Breast CancerSemantic proximity Read

EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progressSemantic proximity Read

Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.Semantic proximity Read

Therapeutic Effects of Dietary Soybean Genistein on Triple-Negative Breast Cancer via Regulation of Epigenetic MechanismsSemantic proximity Read

Transcriptional Rewiring of BET Inhibitor Treated Ewing Sarcoma Cells Augments their Dependency on Focal Adhesion KinaseSemantic proximity Read